Harvard Bioscience, Inc. (HBIO)
USD 0.37
(-3.78%)
USD 0.37
(-3.78%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -3.41 Million USD | 64.11% |
| 2022 | -9.51 Million USD | -3204.17% |
| 2021 | -288 Thousand USD | 96.31% |
| 2020 | -7.81 Million USD | -66.63% |
| 2019 | -4.68 Million USD | -35.38% |
| 2018 | -3.46 Million USD | -300.23% |
| 2017 | -865 Thousand USD | 79.92% |
| 2016 | -4.3 Million USD | 77.38% |
| 2015 | -19.03 Million USD | -908.45% |
| 2014 | 2.35 Million USD | 228.69% |
| 2013 | -1.83 Million USD | -177.22% |
| 2012 | 2.37 Million USD | -37.83% |
| 2011 | 3.81 Million USD | -79.95% |
| 2010 | 19.01 Million USD | 162.89% |
| 2009 | 7.23 Million USD | 332.34% |
| 2008 | 1.67 Million USD | 223.56% |
| 2007 | -1.35 Million USD | 42.16% |
| 2006 | -2.34 Million USD | 92.66% |
| 2005 | -31.87 Million USD | -1468.7% |
| 2004 | 2.32 Million USD | -45.32% |
| 2003 | 4.25 Million USD | 477.71% |
| 2002 | 737.32 Thousand USD | 114.16% |
| 2001 | -5.2 Million USD | 89.56% |
| 2000 | -49.86 Million USD | -69.51% |
| 1999 | -29.41 Million USD | -41536.5% |
| 1998 | 71 Thousand USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -4.69 Million USD | -158.2% |
| 2024 Q2 | -2.92 Million USD | 37.64% |
| 2023 Q3 | -1.23 Million USD | -26.43% |
| 2023 FY | -3.41 Million USD | 64.11% |
| 2023 Q1 | 622 Thousand USD | 137.33% |
| 2023 Q4 | -1.81 Million USD | -46.73% |
| 2023 Q2 | -980 Thousand USD | -257.56% |
| 2022 Q4 | -1.66 Million USD | 51.07% |
| 2022 FY | -9.51 Million USD | -3204.17% |
| 2022 Q3 | -3.4 Million USD | -239.84% |
| 2022 Q2 | 2.43 Million USD | 135.39% |
| 2022 Q1 | -6.88 Million USD | -815.92% |
| 2021 Q4 | 961 Thousand USD | 665.29% |
| 2021 Q1 | -669 Thousand USD | -8.78% |
| 2021 Q3 | -170 Thousand USD | 58.54% |
| 2021 Q2 | -410 Thousand USD | 38.71% |
| 2021 FY | -288 Thousand USD | 96.31% |
| 2020 Q3 | -1.09 Million USD | 30.55% |
| 2020 Q4 | -615 Thousand USD | 43.99% |
| 2020 FY | -7.81 Million USD | -66.63% |
| 2020 Q1 | -4.51 Million USD | 3.65% |
| 2020 Q2 | -1.58 Million USD | 64.99% |
| 2019 FY | -4.68 Million USD | -35.38% |
| 2019 Q3 | -2.62 Million USD | -960.73% |
| 2019 Q4 | -4.68 Million USD | -78.89% |
| 2019 Q2 | -247 Thousand USD | 89.58% |
| 2019 Q1 | -2.37 Million USD | -202.07% |
| 2018 FY | -3.46 Million USD | -300.23% |
| 2018 Q1 | -4.06 Million USD | -506.81% |
| 2018 Q3 | -256 Thousand USD | 82.51% |
| 2018 Q4 | 2.32 Million USD | 1007.03% |
| 2018 Q2 | -1.46 Million USD | 63.98% |
| 2017 Q1 | -1.06 Million USD | 19.24% |
| 2017 FY | -865 Thousand USD | 79.92% |
| 2017 Q4 | 999 Thousand USD | 339.57% |
| 2017 Q3 | -417 Thousand USD | -9.45% |
| 2017 Q2 | -381 Thousand USD | 64.26% |
| 2016 Q3 | -1.63 Million USD | -129.73% |
| 2016 Q4 | -1.32 Million USD | 19.41% |
| 2016 Q1 | -636 Thousand USD | 96.29% |
| 2016 FY | -4.3 Million USD | 77.38% |
| 2016 Q2 | -713 Thousand USD | -12.11% |
| 2015 Q1 | -1.4 Million USD | -7273.68% |
| 2015 Q3 | -847 Thousand USD | -342.69% |
| 2015 Q4 | -17.14 Million USD | -1923.61% |
| 2015 FY | -19.03 Million USD | -908.45% |
| 2015 Q2 | 349 Thousand USD | 124.91% |
| 2014 Q1 | 719 Thousand USD | 195.11% |
| 2014 Q2 | 1.02 Million USD | 42.14% |
| 2014 FY | 2.35 Million USD | 228.69% |
| 2014 Q4 | -19 Thousand USD | -103.0% |
| 2014 Q3 | 633 Thousand USD | -38.06% |
| 2013 FY | -1.83 Million USD | -177.22% |
| 2013 Q4 | -756 Thousand USD | 23.09% |
| 2013 Q3 | -983 Thousand USD | -428.49% |
| 2013 Q2 | -186 Thousand USD | -293.75% |
| 2013 Q1 | 96 Thousand USD | -92.01% |
| 2012 Q3 | -133 Thousand USD | -117.18% |
| 2012 Q4 | 1.2 Million USD | 1003.76% |
| 2012 Q1 | 529 Thousand USD | -28.32% |
| 2012 FY | 2.37 Million USD | -37.83% |
| 2012 Q2 | 774 Thousand USD | 46.31% |
| 2011 Q3 | 28 Thousand USD | -97.96% |
| 2011 Q2 | 1.37 Million USD | -18.26% |
| 2011 Q1 | 1.67 Million USD | -23.22% |
| 2011 FY | 3.81 Million USD | -79.95% |
| 2011 Q4 | 738 Thousand USD | 2535.71% |
| 2010 Q2 | 1.88 Million USD | -15.26% |
| 2010 Q4 | 2.18 Million USD | -82.85% |
| 2010 FY | 19.01 Million USD | 162.89% |
| 2010 Q3 | 12.73 Million USD | 576.41% |
| 2010 Q1 | 2.22 Million USD | -41.43% |
| 2009 Q2 | 281 Thousand USD | -84.72% |
| 2009 Q1 | 1.83 Million USD | -11.42% |
| 2009 FY | 7.23 Million USD | 332.34% |
| 2009 Q4 | 3.79 Million USD | 187.06% |
| 2009 Q3 | 1.32 Million USD | 370.11% |
| 2008 Q1 | 687 Thousand USD | 152.72% |
| 2008 Q4 | 2.07 Million USD | 44.87% |
| 2008 FY | 1.67 Million USD | 223.56% |
| 2008 Q3 | 1.43 Million USD | 164.96% |
| 2008 Q2 | -2.2 Million USD | -421.11% |
| 2007 Q2 | -1.76 Million USD | -456.05% |
| 2007 Q1 | 496 Thousand USD | 120.86% |
| 2007 Q3 | 1.21 Million USD | 169.03% |
| 2007 FY | -1.35 Million USD | 42.16% |
| 2007 Q4 | -1.3 Million USD | -206.89% |
| 2006 Q4 | -2.37 Million USD | -1228.49% |
| 2006 Q2 | -324 Thousand USD | -160.0% |
| 2006 Q1 | 540 Thousand USD | 110.07% |
| 2006 FY | -2.34 Million USD | 92.66% |
| 2006 Q3 | -179 Thousand USD | 44.75% |
| 2005 Q1 | 202 Thousand USD | -82.04% |
| 2005 Q2 | -27.37 Million USD | -13653.96% |
| 2005 Q3 | 661 Thousand USD | 102.41% |
| 2005 Q4 | -5.36 Million USD | -911.04% |
| 2005 FY | -31.87 Million USD | -1468.7% |
| 2004 Q3 | 957 Thousand USD | 221.14% |
| 2004 Q4 | 1.12 Million USD | 17.55% |
| 2004 Q2 | 298 Thousand USD | 684.31% |
| 2004 Q1 | -51 Thousand USD | -102.91% |
| 2004 FY | 2.32 Million USD | -45.32% |
| 2003 FY | 4.25 Million USD | 477.71% |
| 2003 Q2 | 743 Thousand USD | -4.25% |
| 2003 Q3 | 986 Thousand USD | 32.71% |
| 2003 Q4 | 1.75 Million USD | 77.75% |
| 2003 Q1 | 776 Thousand USD | 179.86% |
| 2002 Q2 | 1.01 Million USD | 31.69% |
| 2002 Q3 | -82 Thousand USD | -108.06% |
| 2002 Q1 | 773 Thousand USD | 277.94% |
| 2002 FY | 737.32 Thousand USD | 114.16% |
| 2002 Q4 | -971.67 Thousand USD | -1084.97% |
| 2001 Q2 | -5.36 Million USD | -2072.43% |
| 2001 Q3 | 319 Thousand USD | 105.95% |
| 2001 FY | -5.2 Million USD | 89.56% |
| 2001 Q1 | 272 Thousand USD | -99.2% |
| 2001 Q4 | -434.41 Thousand USD | -236.18% |
| 2000 FY | -49.86 Million USD | -69.51% |
| 2000 Q1 | -27.95 Million USD | 0.0% |
| 2000 Q4 | 33.99 Million USD | 221.6% |
| 2000 Q3 | -27.95 Million USD | 0.0% |
| 2000 Q2 | -27.95 Million USD | 0.0% |
| 1999 FY | -29.41 Million USD | -41536.5% |
| 1998 FY | 71 Thousand USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Akoya Biosciences, Inc. | -63.32 Million USD | 94.607% |
| AngioDynamics, Inc. | -184.34 Million USD | 98.148% |
| AtriCure, Inc. | -30.43 Million USD | 88.78% |
| Avinger, Inc. | -18.32 Million USD | 81.359% |
| Azenta, Inc. | -14.25 Million USD | 76.047% |
| BioLife Solutions, Inc. | -66.42 Million USD | 94.859% |
| The Cooper Companies, Inc. | 294.2 Million USD | 101.161% |
| Daxor Corporation | 280.64 Thousand USD | 1316.861% |
| Ekso Bionics Holdings, Inc. | -15.19 Million USD | 77.53% |
| Femasys Inc. | -14.24 Million USD | 76.03% |
| GlucoTrack, Inc. | -7.09 Million USD | 51.881% |
| Hologic, Inc. | 789.5 Million USD | 100.433% |
| ICU Medical, Inc. | -29.65 Million USD | 88.484% |
| Intuitive Surgical, Inc. | 1.79 Billion USD | 100.19% |
| KORU Medical Systems, Inc. | -13.74 Million USD | 75.147% |
| LeMaitre Vascular, Inc. | 30.1 Million USD | 111.344% |
| Innovative Eyewear, Inc. | -6.66 Million USD | 48.75% |
| Innovative Eyewear, Inc. | -6.66 Million USD | 48.75% |
| Masimo Corporation | 81.5 Million USD | 104.19% |
| Microbot Medical Inc. | -10.74 Million USD | 68.203% |
| Meihua International Medical Technologies Co., Ltd. | 11.62 Million USD | 129.375% |
| Merit Medical Systems, Inc. | 94.41 Million USD | 103.617% |
| Nephros, Inc. | -1.57 Million USD | -116.825% |
| NovoCure Limited | -207.04 Million USD | 98.351% |
| NEXGEL, Inc. | -3.15 Million USD | -8.172% |
| NEXGEL, Inc. | -3.15 Million USD | -8.172% |
| Singular Genomics Systems, Inc. | -94.82 Million USD | 96.398% |
| OraSure Technologies, Inc. | 53.65 Million USD | 106.365% |
| Pro-Dex, Inc. | 2.12 Million USD | 260.555% |
| Pulse Biosciences, Inc. | -42.21 Million USD | 91.91% |
| Predictive Oncology Inc. | -13.98 Million USD | 75.579% |
| Precision Optics Corporation, Inc. | -2.95 Million USD | -15.709% |
| QuidelOrtho Corporation | -10.1 Million USD | 66.188% |
| Repligen Corporation | 41.57 Million USD | 108.214% |
| Sanara MedTech Inc. | -4.3 Million USD | 20.64% |
| STAAR Surgical Company | 21.34 Million USD | 115.998% |
| Sharps Technology, Inc. | -9.84 Million USD | 65.3% |
| Utah Medical Products, Inc. | 16.63 Million USD | 120.529% |
| DENTSPLY SIRONA Inc. | -132 Million USD | 97.413% |
| Jin Medical International Ltd. | 2.87 Million USD | 218.649% |